The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with platinum-doublet chemotherapy to treat adults with resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting.
The combination—to be administered every three weeks for three cycles—was approved regardless of programmed death ligand-1 tumor expression level.
“The approval of nivolumab with platinum-doublet chemotherapy marks a turning point in how we treat resectable NSCLC and it